- Home
- WGS vs RVMD Comparison
WGS vs RVMD Comparison
Compare WGS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WGS | RVMD |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 7.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WGS | RVMD |
|---|---|---|
| Price | $151.25 | $78.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 18 |
| Target Price | ★ $135.00 | $77.11 |
| AVG Volume (30 Days) | 445.9K | ★ 2.1M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $402,190,000.00 | N/A |
| Revenue This Year | $41.17 | N/A |
| Revenue Next Year | $23.53 | $714.50 |
| P/E Ratio | $2,060.27 | ★ N/A |
| Revenue Growth | ★ 50.50 | N/A |
| 52 Week Low | $55.17 | $29.17 |
| 52 Week High | $170.87 | $81.49 |
Technical Indicators
Market Signals| Indicator | WGS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.64 | 73.68 |
| Support Level | $156.17 | $77.54 |
| Resistance Level | $165.62 | $81.49 |
| Average True Range (ATR) | 7.91 | 2.51 |
| MACD | -1.42 | -0.48 |
| Stochastic Oscillator | 19.44 | 75.46 |
Price Performance
Historical ComparisonAbout WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.